Important Notice for TransMedics Group, Inc. (TMDX) Shareholders: Potential Securities Class Action
New York, NY – The Gross Law Firm, a leading national shareholder rights law firm, announces that it has commenced an investigation on behalf of purchasers of TransMedics Group, Inc. (NASDAQ: TMDX) shares between February 1, 2023, and March 31, 2025, inclusive (the “Class Period”).
The investigation concerns allegations that TransMedics and certain of its officers and/or directors may have violated federal securities laws. Specifically, the investigation concerns whether the Company and its executives misrepresented or failed to disclose material information about the Company’s business, operations, and financial condition.
Background
TransMedics is a medical technology company that specializes in organ preservation and transplantation. The Company’s Organ Care System (OCS) is designed to maintain major organs outside the body until transplant, extending the time between donor and recipient by hours.
Allegations
The investigation focuses on whether TransMedics and its executives made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing production and logistical issues with its OCS; (2) that the Company’s financial results were negatively impacted by these issues; and (3) that, as a result of the foregoing, Defendants’ statements about TransMedics’ business, operations, and prospects were materially false and/or misleading at all relevant times.
Class Period and Lead Plaintiff Process
The Class Period is the period from February 1, 2023, to March 31, 2025. The Lead Plaintiff is the court-appointed representative of the class. The Deadline to Move for Appointment as Lead Plaintiff is June 6, 2025. The Gross Law Firm encourages shareholders who purchased or otherwise acquired TMDX securities during the Class Period to contact the firm regarding this investigation and potential lead plaintiff appointment.
Effects on Shareholders
If you purchased TMDX securities during the Class Period, you may be able to recover damages for your losses. The Gross Law Firm invites you to contact the firm to discuss your legal rights and potential remedies. You can also join the conversation by contacting The Gross Law Firm’s Securities Class Action Coordinator, Jules Zoet, at 212-504-5453, [email protected], or fill out the form on our website: www.grosslawfirm.com/contact/.
Effects on the World
The potential securities class action against TransMedics may have far-reaching implications, particularly for the medical technology industry and its investors. The case could set a precedent for how companies disclose production and logistical issues that impact their financial performance. It could also impact investor confidence in the medical technology sector and potentially lead to increased regulatory scrutiny.
Conclusion
The Gross Law Firm is committed to ensuring that shareholders receive the compensation they deserve. If you purchased TMDX securities during the Class Period, you may be entitled to damages for your losses. The Gross Law Firm encourages you to contact the firm to discuss your legal rights and potential remedies. For more information about this investigation and class action, please visit www.grosslawfirm.com/transmedics/.
About The Gross Law Firm: The Gross Law Firm is a leading national securities fraud class action law firm representing purchasers in securities fraud, breach of fiduciary duty, and related shareholder derivative litigation. The firm seeks recovery on behalf of investors and seeks to hold corporate defendants accountable for their misconduct. To learn more about The Gross Law Firm, please visit www.grosslawfirm.com.
- TransMedics Group, Inc.
- NASDAQ: TMDX
- February 1, 2023 – March 31, 2025
- Securities Class Action
- The Gross Law Firm
- www.grosslawfirm.com/transmedics/
